The extracorporeal CO₂ removal devices market size is estimated to be USD 85.49 million in 2022 and is expected to witness a CAGR of 7.57% during the forecast period 2023-2033. Increase in COPD cases, technological developments, escalating product launches, and product approval are factors contributing to the market growth. Additionally, rising frequency of chronic obstructive lung diseases and other respiratory disorders is projected to support the market growth. However, rising concerns towards adverse effects of extracorporeal CO₂ removal devices is expected to hinder the growth.

Increase in COPD cases is expected to propel the market growth during the forecast period. For the formation of ultraprotective or protective conditions in ARDS patients, and in patients with severe COPD exacerbations, extracorporeal CO2 removal devices are used. By removing blood CO2, extracorporeal CO2 removal devices combat the negative consequences of hypercapnia and the associated acidosis. The WHO estimates that COPD contributed to 3.23 million deaths in 2019 and is the third highest cause of mortality worldwide. Additionally, the American Lung Association reports that more than 11 million Americans are diagnosed with COPD annually.

Technological developments are predicted to fuel the market growth during the projected period. Extracorporeal respiratory assist systems (ERAS) have recently undergone technological developments, which has increased interest in extracorporeal carbon dioxide removal (ECCOR) devices. For instance, Alung Technologies gained De Novo Clearance for the hemolung respiratory system in November 2021. The FDA has only now given this system its approval seal. X-COR Therapeutics completed a funding round of around 2.6 million in November 2020. This business plans to use these funds to continue developing its products, such as ECCO2R devices.

Segmentation

By Product

The market is categorized into disposables, extracorporeal co₂ machines, and others. In the global market, the extracorporeal co₂ machines segment accounted for the largest revenue share in 2022 owing to growing benefits related to extracorporeal co₂ machines. The research and prospective uses of extracorporeal CO2 extraction devices have advanced quickly as a result of technical simplification, mostly avoiding the early issues related to ECMO. Theoretically easier and requiring less people and logistical support are the advantages of extracorporeal CO2 removal devices, which increases patient preference. The disposables segment is anticipated to grow at a robust CAGR over the projection period. In extracorporeal CO2 removal therapy, disposables are used on a per-procedure, per-patient basis. The market is expected to expand as a result of high consumable consumption and demand in extracorporeal carbon dioxide removal techniques. Therefore, it is projected that during the course of the analysis period, demand for extracorporeal CO2 removal devices will increase due to the growing requirement for disposables for a number of COPD and ARDS-related treatments.

 By Access

The market is divided into arteriovenous and venovenous. In 2022, the venovenous segment accounted for the highest revenue share due to increase in patient use of venovenous extracorporeal CO2 removal devices. In venovenous access, blood is taken from the central vein through a drainage cannula using a centrifugal pump or roller to create flow over the gas exchange membrane. Extracorporeal CO2 removal devices of a new generation have been created recently. The arterio-venous approach is being replaced by effective venovenous extracorporeal CO2 removal devices, which have the advantage of not requiring arterial puncture. In 2022, the arteriovenous market had a sizable value. With arteriovenous extracorporeal CO2 removal devices, blood passes via a gas exchanger in the femoral artery and then returns to the opposite femoral vein. The arteriovenous system makes use of a high-tech, simplified membrane lung with extremely low blood flow resistance, high gas transfer efficiency, and no heat exchanger.

 By Application

The market is segregated into bridge to lung transplant, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), others. In the global market, the bridge to lung transplant segment accounted for the largest revenue share in 2022 owing to the fact that extracorporeal CO2 removal devices may be helpful for patients waiting lung transplantation who have life-threatening hypercarbia by serving as a stopgap measure until transplantation. During the forecast period, it is projected that manufacturers including Alung Technologies, Xenios AG, and others would increase their focus on creating extracorporeal CO2 removal devices as a bridge to lung transplantation. The ARDS segment is expected to register fastest CAGR during the forecast period. Extracorporeal CO2 removal devices are in high demand in patients with ARDS due to its capacity to remove CO2 and aid in enabling lung protective ventilation by reducing plateau pressures and tidal volume.

 By End Use

The market is segmented into clinics, hospitals, ambulatory surgical centers, and others. In 2022, the hospitals segment accounted for the largest revenue share owing to rise in hospital admissions, particularly ARDS patients. The market for extracorporeal CO2 removal devices is also projected to increase due to increasing COPD and ARDS incidence. Rising patient hospitalization rates and an increase in the number of hospitals around the world are anticipated to fuel market expansion over the forecast period. A significant portion of the market is expected to be represented by ambulatory surgery centres. This increase is attributable to an increase in the incidence of acute respiratory failure in rural areas with poor access to healthcare services. Ambulatory surgical centres also provide improved patient accessibility, reduced out-of-pocket expenses, and lower facility costs. Therefore, it is projected that increased demand for ambulatory surgery facilities would fuel market expansion.

Regional Markets

In 2022, North America region accounted for the highest revenue in the extracorporeal CO₂ removal devices market and is expected to maintain its dominance during the forecast period. This is attributed to rising demand among healthcare workers for extracorporeal CO2 removal devices. It is anticipated that enhanced healthcare infrastructure and widespread use of extracorporeal CO2 removal devices, particularly during the COVID-19 outbreak in the U.S. and Canada, is estimated to boost North America capture a larger share of the global market. The market expansion in North America is expected to be accelerated by early adoption of novel technologies and a sizable patient population with ARDS and COPD. The market is expected to develop at the fastest rate in Asia Pacific, which currently dominates the global market. The presence of a sizable patient pool, growing public awareness of acute respiratory failure, and increased government spending on healthcare in developing countries including Japan and India are expected to accelerate regional market expansion.

Competitor Insights

Some of the key players operating in the extracorporeal CO₂ removal devices market are Alung Technologies, Medica Spa, Getinge AB, ESTOR S.P.A, Xenios AG, Medtronic, and Aferectica Srl.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, in April 2022, Getinge joins the International Finance Corporation (IFC) programme to support doctors in East and West Africa in getting greater access to life-saving supplies. The Africa Medical Equipment Facility (AMEF) is a project run by the International Finance Corporation (IFC) in partnership with global Medtech suppliers to help small and medium-sized health care providers in East and West Africa get local-currency loans to buy or lease required medical equipment.
• The Food and Drug Administration (FDA) granted ALung Technologies Inc. De Novo clearance for the Hemolung Respiratory Assist System in November 2021. The FDA has only approved the Hemolung System as an ECCO2R device.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including product, access, application, and end use from 2023 to 2033.

Report Scope:

Segmentation: Extracorporeal CO₂ Removal Devices Market Report 2022 – 2033

Product (Revenue, USD Million), 2022 – 2033

• Disposables
• Extracorporeal CO₂ Machines
• Others

Access (Revenue, USD Million), 2022 – 2033

• Arteriovenous
• Venovenous

Application (Revenue, USD Million), 2022 – 2033

• Bridge to Lung Transplant
• Chronic Obstructive Pulmonary Disease (COPD)
• Acute Respiratory Distress Syndrome (ARDS)
• Others

End Use (Revenue, USD Million), 2022 – 2033

• Clinics
• Hospitals
• Ambulatory Surgical Centers
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA